NCAM1 and myeloid sarcoma: Correspondingly, soluble NCAM levels in MS patients decreases in a step-wise manner through the various stages of disease, starting from first presentation and progressing towards fixed disability, and there's no appreciable difference in NCAM levels with relapses.